Fecal Microbiota-Based Screening Feasible for Pancreatic Cancer
Fecal metagenomics classifiers better than salivary-based classifiers for identifying pancreatic ductal adenocarcinoma
Fecal metagenomics classifiers better than salivary-based classifiers for identifying pancreatic ductal adenocarcinoma
The approval was based on data from the phase 3 COSMIC-311 study.
The accelerated approval was based on data from the phase 1 GARNET trial.
The sNDA is supported by data from the phase 3 COSMIC-311 study.
Evidence-based guidelines address diagnosis, evaluation, and treatment, including early multidisciplinary care team involvement
Lenvatinib was associated with the most significant probability of producing all grades of cardiovascular injury and hypertension.
The designation is supported by data from the randomized, double-blind, placebo-controlled phase 3 COSMIC-311 study.
The approval was based on data from the phase 1/2 ARROW trial which evaluated the efficacy and safety of Gavreto in patients with RET-mutant MTC.
Detectnet (copper Cu 64 dotatate) is indicated for use with PET for localization of somatostatin receptor positive neuroendocrine tumors.
Zenocutuzumab is a first-in-class bispecific antibody that binds to HER2 and HER3 receptors, thereby blocking the interaction of HER3 with its ligand neuregulin 1 (NRG1) or NRG1-fusion proteins.